US FDA approves LEQSELVI, an Oral JAK Inhibitor for treatment of severe Alopecia Areata
LEQSELVI delivered statistically significant efficacy across two Phase 3 clinical trials At baseline, the average patient had only 13% scalp ...
LEQSELVI delivered statistically significant efficacy across two Phase 3 clinical trials At baseline, the average patient had only 13% scalp ...
